{"denoms":[{"counts":[{"groupId":"BG000","value":"278"},{"groupId":"BG001","value":"281"},{"groupId":"BG002","value":"559"}],"units":"Participants"}],"groups":[{"description":"Participants received pembrolizumab 200 mg by intravenous (IV) infusion prior to chemotherapy on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (\\~ 2 years) PLUS Investigator's choice of paclitaxel (200 mg/m\\^2 by IV infusion on Day 1 of each 21-day cycle for 4 cycles) or nab-paclitaxel (100 mg/m\\^2 by IV infusion on Days 1, 8, 15 of each 21-day cycle for 4 cycles) PLUS carboplatin Area Under Curve (AUC) 6 by IV infusion on Day 1 of each 21-day cycle for 4 cycles. Participants who received pembrolizumab 200 mg IV Day 1 of 21-day cycle for up to 2 years, but experienced disease progression, were eligible to receive a second course of pembrolizumab 200 mg IV Day 1 of 21-day cycle, at the investigator's discretion, for 17 cycles (\\~ 1 year additional).","id":"BG000","title":"Pembrolizumab + Chemotherapy Combo"},{"description":"Participants received normal saline as placebo by IV infusion prior to chemotherapy on Day 1 of 21-day cycle for up to 35 cycles (\\~ 2 years) PLUS Investigator's choice of paclitaxel (200 mg/m\\^2 by IV infusion on Day 1 of each 21-day cycle for 4 cycles) or nab-paclitaxel (100 mg/m\\^2 by IV infusion on Days 1, 8, 15 of each 21-day cycle for 4 cycles) PLUS carboplatin AUC 6 by IV infusion on Day 1 of each 21-day cycle for 4 cycles. Participants with documented disease progression following placebo chemotherapy combo could switch-over to receive pembrolizumab for up to 35 cycles (\\~ 2 years). Eligible cross over participants who stopped pembrolizumab and had stable disease but progressed after discontinuation, initiated a second course of pembrolizumab at the investigator's discretion for up to 17 cycles (\\~ 1 year additional).","id":"BG001","title":"Placebo + Chemotherapy"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"8.8","value":"65.0"},{"groupId":"BG001","spread":"8.7","value":"64.8"},{"groupId":"BG002","spread":"8.7","value":"64.9"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"58"},{"groupId":"BG001","value":"46"},{"groupId":"BG002","value":"104"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"220"},{"groupId":"BG001","value":"235"},{"groupId":"BG002","value":"455"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"2"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"56"},{"groupId":"BG001","value":"52"},{"groupId":"BG002","value":"108"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"7"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"216"},{"groupId":"BG001","value":"214"},{"groupId":"BG002","value":"430"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"11"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"95"},{"groupId":"BG001","value":"99"},{"groupId":"BG002","value":"194"}],"title":"TPS <1%"},{"measurements":[{"groupId":"BG000","value":"176"},{"groupId":"BG001","value":"177"},{"groupId":"BG002","value":"353"}],"title":"TPS ≥1%"},{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"12"}],"title":"Unknown"}]}],"description":"Participants were assessed for their PD-L1 tumor expression level by immunohistochemistry assay using tumor tissue from a newly obtained biopsy. Participants with a TPS ≥1% were classified as PD-L1 positive and participants with a TPS \\<1% were classified as not PD-L1 positive.","paramType":"COUNT_OF_PARTICIPANTS","title":"Programmed Cell Death-Ligand 1 (PD-L1) Tumor Expression Level: Tumor Proportion Score (TPS)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"169"},{"groupId":"BG001","value":"167"},{"groupId":"BG002","value":"336"}],"title":"+Paclitaxel"},{"measurements":[{"groupId":"BG000","value":"109"},{"groupId":"BG001","value":"114"},{"groupId":"BG002","value":"223"}],"title":"+Nab-paclitaxel"}]}],"description":"Participants were classified according to their taxane chemotherapy regimen: paclitaxel or nab-paclitaxel.","paramType":"COUNT_OF_PARTICIPANTS","title":"Taxane Chemotherapy","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"54"},{"groupId":"BG001","value":"52"},{"groupId":"BG002","value":"106"}],"title":"East Asia"},{"measurements":[{"groupId":"BG000","value":"224"},{"groupId":"BG001","value":"229"},{"groupId":"BG002","value":"453"}],"title":"Non-East Asia"}]}],"description":"Participants were classified according to their geographic region: East Asia vs. non-East Asia.","paramType":"COUNT_OF_PARTICIPANTS","title":"Geographic Region","unitOfMeasure":"Participants"}]}